News

Trevi Therapeutics Announces Closing of $115 Million Underwritten Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares
Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy ...
Trevi Therapeutics Announces Proposed Public Offering of Common Stock
Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy ...
Oppenheimer Boosts Trevi Therapeutics (TRVI) PT to $23, Cites Positive Haduvio Trial Results
Oppenheimer increased its price target for Trevi Therapeutics Inc. (NASDAQ:TRVI) to $23 from $20, while maintaining an ...
Oppenheimer Raises Price Target for Trevi Therapeutics by $3
Oppenheimer maintained its Outperform rating on Trevi Therapeutics, Inc. (NASDAQ:TRVI) shares and lifted the price target ...
Trevi Therapeutics Announces Pricing Of $100 Million Underwritten Offering Of Common Stock
Morgan Stanley, Leerink Partners, Stifel and Cantor are acting as joint book-running managers for the offering.
Morningstar3d
Trevi Therapeutics Announces Positive Topline Results from the Phase 2b CORAL Trial of Haduvio in Patients with Idiopathic Pulmonary Fibrosis Chronic Cough
President and CEO of Trevi Therapeutics. "Chronic cough is one of the most debilitating comorbidities for patients with IPF, impacting an estimated 85% of these patients. There are no approved ...
Trevi Therapeutics Showcases Drug That Cuts Cough Frequency In Lung Disease Patients
Trevi's Haduvio met its primary endpoint in a Phase 2b trial for IPF-related chronic cough, with statistically significant ...
Morningstar3d
Trevi Therapeutics Announces Proposed Public Offering of Common Stock
NEW HAVEN, Conn., June 2, 2025 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral ...